TAK-632 - 98%, high purity , CAS No.1228591-30-7, Inhibitor of aurora kinase B;Inhibitor of B-Raf proto-oncogene; serine/threonine kinase;Inhibitor of fibroblast growth factor receptor 3;Inhibitor of platelet derived growth factor receptor beta;Inhibitor of Raf-1 proto-oncogene; serine/threonine kinase;I

Item Number
T413733
Grouped product items
SKUSizeAvailabilityPrice Qty
T413733-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$32.90
T413733-10mg
10mg
3
$53.90
T413733-25mg
25mg
3
$121.90
T413733-50mg
50mg
2
$162.90
T413733-100mg
100mg
2
$293.90

C-Raf/Raf-1 Selective Inhibitors.

Basic Description

SynonymsN-[7-cyano-6-[4-fluoro-3-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]phenoxy]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide | N-(7-cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsTAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of aurora kinase B;Inhibitor of B-Raf proto-oncogene; serine/threonine kinase;Inhibitor of fibroblast growth factor receptor 3;Inhibitor of platelet derived growth factor receptor beta;Inhibitor of Raf-1 proto-oncogene; serine/threonine kinase;I
Product Description

Information

TAK-632 is a potent pan-Rafinhibitor withIC50of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.


Targets

C-Raf (Cell-free assay); B-Raf (Cell-free assay); Aurora B (Cell-free assay); PDGFRβ (Cell-free assay); FGFR3 (Cell-free assay) 15112,1.4 nM; 8.3 nM; 66 nM ;120 nM; 280 nM


In vitro

TAK-632 inhibits phosphorylation of MEK and ERK in melanoma A375 cells (BRAFV600E) with IC50 of 12 nM and 16 nM, respectively. In human melanoma HMVII cells (NRASQ61K/BRAFG469V), TAK-632 also shows strong inhibition of pMEK and pERK with IC50 of 49 nM and 50 nM, respectively. Moreover, TAK-632 also exhibits antiproliferative activity in both A375 and HMVII cells with GI50 of 66 nM and 200 nM, respectively. TAK-632 induces RAF dimerization but inhibits the kinase activity of the RAF dimer because of its slow dissociation from RAF. The combination of TAK-632 and TAK-733 exhibits synergistic antiproliferative effects in BRAF- and NRAS-mutated melanoma cells.


In vivo

TAK-632 shows superior oral bioavailability in both rats and dogs. TAK-632 (3.9–24.1 mg/kg, p.o.) exhibits dose-dependent antitumor efficacy without severe body weight reduction in a melanoma A375 (BRAFV600E) xenograft model and a human melanoma HMVII (NRASQ61K/BRAFG469V) xenograft in rats. In NRAS-mutant melanoma SK-MEL-2 xenograft model, TAK-632 (60 or 120 mg/kg, p.o.) also exhibits potent antitumor efficacy without severe toxicity.


Cell Research(from reference)

Cell lines:A375 and HMVII cells 

Concentrations:~2 μM 

Incubation Time:72 hours 

AI Insight

Product Properties

ALogP5.74
HBD Count2
Rotatable Bond8

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid504770683
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/504770683
IUPAC Name N-[7-cyano-6-[4-fluoro-3-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]phenoxy]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide
INCHI InChI=1S/C27H18F4N4O3S/c28-19-7-6-17(12-21(19)33-23(36)11-14-2-1-3-16(10-14)27(29,30)31)38-22-9-8-20-24(18(22)13-32)39-26(34-20)35-25(37)15-4-5-15/h1-3,6-10,12,15H,4-5,11H2,(H,33,36)(H,34,35,37)
InChi Key OJFKUJDRGJSAQB-UHFFFAOYSA-N
Canonical SMILES C1CC1C(=O)NC2=NC3=C(S2)C(=C(C=C3)OC4=CC(=C(C=C4)F)NC(=O)CC5=CC(=CC=C5)C(F)(F)F)C#N
Isomeric SMILES C1CC1C(=O)NC2=NC3=C(S2)C(=C(C=C3)OC4=CC(=C(C=C4)F)NC(=O)CC5=CC(=CC=C5)C(F)(F)F)C#N
PubChem CID 46209401
MeSH Entry Terms N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo(d)thiazol-2-yl)cyclopropanecarboxamide;TAK-632
Molecular Weight 554.52

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

4 results found

Lot NumberCertificate TypeDateItem
H2224297Certificate of AnalysisJun 20, 2022 T413733
H2224298Certificate of AnalysisJun 20, 2022 T413733
H2224299Certificate of AnalysisJun 20, 2022 T413733
H2224300Certificate of AnalysisJun 20, 2022 T413733

Safety and Hazards(GHS)

Pictogram(s) GHS07
Signal Warning
Hazard Statements

H302:Harmful if swallowed

Precautionary Statements

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

Related Documents

Reviews

Customer Reviews

References

1. Okaniwa M, Hirose M, Arita T, Yabuki M, Nakamura A, Takagi T, Kawamoto T, Uchiyama N, Sumita A, Tsutsumi S et al..  (2013)  Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives..  J Med Chem,  56  (16): (6478-94).  [PMID:23906342] [10.1021/op500134e]

Solution Calculators